MS

ICON is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. We specialize in the strategic development, management and analysis of programs that support Clinical Development – from compound selection to Phase I - IV clinical studies

Merck and Schering-Plough merged in November 2009 to create a new company. Today, they are the second-largest healthcare company in the world. They also are a global leader in consumer products and animal care.

Dr. Reddy's Laboratories (NYSE: RDY) is an emerging global pharmaceutical company with proven research capabilities. The company is vertically integrated with a presence across the pharmaceutical value chain. It produces finished dosage forms, active pharmaceutical ingredients and biotechnology products and markets them globally, with focus on India, US, Europe and Russia.

Syngene International is one of India’s premier contract research and manufacturing organizations in providing customized service. Our services encompasses all across discovery chain: early stage discovery, process development, cGMP manufacturing and formulation development both in the small molecule and novel biologics area.

Bristol-Myers Squibb Biocon R&D Center (BBRC) is a collaboration between Bristol-Myers Squibb and Syngene International, a subsidiary of the Indian biotechnology major, Biocon. This initiative is intended to help advance Bristol-Myers Squibb's work in discovery and early drug development. The center is expanding its capabilities to clinical biomarkers, toxicology and first-in-human studies.

National Institute of Pharmaceutical Education and Research (NIPER) is the first national level institute in pharmaceutical sciences with a proclaimed objective of becoming a centre of excellence for advanced studies and research in pharmaceutical sciences. The Government of India has declared NIPER as an ‘Institute of National Importance’.